Browsing by Author "Muga, Silvia de"

Sort by: Order: Results:

  • Agell, Laia; Hernández, Silvia; Nonell Mazelón, Lara; Lorenzo Perez, Marta; Puigdecanet Riubugent, Eulàlia; Muga, Silvia de; Juanpere, Nuria; Bermudo, Raquel; Fernández, Pedro Luís; Lorente Garin, José Antonio; Serrano Figueras, Sergi; Lloreta, Josep, 1958- (Elsevier, 2012)
    The main challenge for clinical management of prostate cancer is to distinguish tumors that will progress faster and will show a higher tendency to recur from the more indolent ones. We have compared expression profiles ...
  • Hernández Llodrà, Silvia; Juanpere, Nuria; Muga, Silvia de; Lorenzo Perez, Marta; Gil Ortega, Joan; Font Tello, Alba 1990-; Agell, Laia; Albero-González, Raquel; Segalés, Laura; Merino, José; Serrano, Laia; Fumadó Ciutat, Lluis; Cecchini Rosell, Lluís; Lloreta, Josep, 1958- (Impact Journals, 2017)
    TMPRSS2 and SLC45A3 rearrangements may coexist in the same tumor. ERG rearrangements and PTEN loss are concomitant events in prostate cancer (PrCa), and can cooperate in progression. We have reported that mRNA expression ...
  • Lloreta, Josep, 1958-; Font-Tello, Alba; Juanpere, Nuria; Frances, Albert; Lorenzo Perez, Marta; Nonell Mazelón, Lara; Muga, Silvia de; Vázquez‐de las Heras, Ivonne; Cecchini Rosell, Lluís; Hernández, Silvia (Elsevier, 2017)
    Nuclear FOXOs mediate cell cycle arrest and promote apoptosis. FOXOs and p53 could have similar effects as tumor suppressor genes. In spite of extensive literature, little is known about the role of FOXO1 and its relationship ...
  • Bellmunt Molins, Joaquim, 1959-; Werner, Lillian; Bamias, Aristotle; Fay, André P.; Park, Rachel S.; Riester, Markus; Selvarajah, Shamini; Barletta, Justine A.; Berman, David M.; Muga, Silvia de; Salido, Marta; Gallardo, Enrique; Rojo, Federico; Guancial, Elizabeth A.; Bambury, Richard; Mullane, Stephanie A.; Choueiri, Toni K.; Loda, Massimo; Stack, Edward; Rosenberg, Jonathan E. (Wiley, 2015)
    We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ...
  • Bellmunt Molins, Joaquim, 1959-; Selvarajah, Shamini; Rodig, Scott; Salido Galeote, Marta; Muga, Silvia de; Costa, Irmgard; Bellosillo Paricio, Beatriz; Werner, Lillian; Mullane, Stephanie A.; Fay, André P.; O’Brien, Robert; Barretina, Jordi; Minoche, André E.; Signoretti, Sabina; Montagut Viladot, Clara; Himmelbauer, Heinz; Berman, David M.; Kantoff, Philip; Choueiri, Toni K.; Rosenberg, Jonathan E. (Public Library of Science (PLoS), 2014)
    Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking